CastleKnight Management’s Teva Pharmaceuticals TEVA Stock Holding History

CastleKnight Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-245,200	Closed	-$7.65M	–	493
2025 Q4	$7.65M	Sell	245,200 -383,900	-61%	-$9.46M	0.17%	78
2025 Q3	$12.7M	Sell	629,100 -37,500	-6%	-$659K	0.25%	57
2025 Q2	$11.2M	Buy	666,600 +524,400	+369%	+$8.46M	0.32%	50
2025 Q1	$2.19M	Sell	142,200 -25,200	-15%	-$450K	0.09%	143
2024 Q4	$3.69M	Sell	167,400 -51,500	-24%	-$937K	0.11%	113
2024 Q3	$3.94M	Sell	218,900 -51,600	-19%	-$903K	0.16%	81
2024 Q2	$4.4M	Sell	270,500 -7,300	-3%	-$112K	0.22%	69
2024 Q1	$3.92M	Buy	277,800 +42,100	+18%	+$531K	0.23%	71
2023 Q4	$2.46M	Buy	+235,700	New	+$2.2M	0.13%	98

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CastleKnight Management's TEVA Position: Q1 2026 in Review

CastleKnight Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 245,200 shares — an estimated $7.65M sold.

CastleKnight Management first reported a position in TEVA in Q4 2023 and held it in 9 quarters. The position peaked at $12.7M in Q3 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

CastleKnight Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
CastleKnight Management sold 245,200 Teva Pharmaceuticals shares in Q1 2026, an estimated $7.65M.
CastleKnight Management first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 9 quarters.
CastleKnight Management's Teva Pharmaceuticals position peaked at $12.7M in Q3 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on CastleKnight Management's 13F filing for Q1 2026, filed 15 May 2026.